Completed
Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm
What is being collected
Data Collection
Other
Who is being recruted
Eye Diseases
+ Eyelid Diseases
+ Blepharospasm
From 18 to 81 Years
+4 Eligibility Criteria
How is the trial designed
Other
Utilizing specific methods not covered by standard models in order to address unique research questions.Observational
Study Start: September 2012
Summary
Principal SponsorMerz Pharmaceuticals GmbH
Last updated: October 28, 2022
Sourced from a government-validated database.Claim as a partner
Study start date: September 1, 2012
Actual date on which the first participant was enrolled.This study is open to males and females > 18 years and < 81 years with a clinical diagnosis of blepharospasm.
Principal SponsorMerz Pharmaceuticals GmbH
Last updated: October 28, 2022
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
124 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Other
Some studies use unique or mixed approaches that don't fit standard categories. These may include innovative observational methods or studies tailored to specific research questions.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.From 18 to 81 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Eye DiseasesEyelid DiseasesBlepharospasm
Criteria
3 inclusion criteria required to participate
Currently receiving incobotulinumtoxinA, abobotulinumtoxinA or onabotulinumtoxinA
Documented clinical diagnosis of blepharospasm
Male or female subject aged > 18 years and < 81 years
1 exclusion criteria prevent from participating
Previous treatment with rimabotulinumtoxinB in the last 2 treatment cycles
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Treatment Groups
Study Objectives
One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 5 locations
Merz Investigative Site #0007
Fountain Valley, United StatesOpen Merz Investigative Site #0007 in Google MapsMerz Investigative Site # 0002
Sarasota, United StatesMerz Investigative Site # 0001
Boston, United StatesMerz Investigative Site #003
Durham, United StatesCompleted5 Study Centers